News Headlines Article

Amid flood of CBD products, FDA holds first public hearing on cannabis extract
The Washington Post

With thousands of unproven CBD products flooding the market, the Food and Drug Administration convenes its first public hearing Friday to wrestle with how to regulate cannabidiol, a cannabis extract already being sold in pills, tinctures, skin lotions, sodas and dog food.

The CBD industry has exploded in recent years as companies have trumpeted the compound’s alleged health benefits — claiming it can reduce anxiety, pain and insomnia and treat conditions from Parkinson’s disease to cancer. But almost all such claims lack rigorous scientific proof, prompting concern among health officials and scientists about safety and deceptive marketing.